Product Name: PMEK (28-36)
Product Number: PE-01AFT80
Size: | 200 µg | | Price: | 22.00 |
| 1 mg | | $US | 43.00 |
| 5 mg | | | 94.00 |
Peptide Name: PMEK (28-36)
Peptide Production Method: Solid-phase peptide synthesis
Peptide Origin: Homo sapiens
Peptide Sequence: KVPRNQDWL
Peptide Modifications N Terminus: Free amino
Peptide Modifications C Terminus: Amide
Peptide Molecular Mass Calculated: 1154.3 Da
Peptide Purity Percent after Synthesis and Purification: >80
Peptide Appearance: White powder
Peptide Form: Solid
Storage Conditions: -20°C
References[1] W.W. Overwijk, A. Tsung, K.R. Irvine, M.R. F.Parkhust, T.J. Goletz, K. Tsung, M.W. Carroll, C. Liu, B. Moss, S.A. Rosenber, and N.P. Restifo, gp100/pmel 17 Is a Murine Tumor Rejection Antigen: Induction of “Self”-reactive, Tumoricidal T Cells Using High-affinity, Altered Peptide Ligand. J. Exper. Med., 188, 277 (1998).[2] Jose Pulido, Timothy Kottke, Jill Thompson, Feorillo Galivo, Phonphimon Wongthida, Rosa Maria Diaz, Diana Rommelfanger, Elizabeth Ilett, Larry Pease, Hardev Pandha, Kevin Harrington, Peter Selby, Alan Melcher & Richard Vile. Using virally expressed melanoma cDNA libraries to identify tumor-associated antigens that cure melanoma. Nature Biotechnology 30, 337–343 (2012), doi:10.1038/nbt.2157 [3] J. Leitch, K. Fraser, C. Lane, K. Putzu, G. J. Adema, Q.-J., Zhang, W. A. Jefferies, J. L. Bramson, Y. Wan. CTL-Dependent and -Independent Antitumor Immunity Is Determined by the Tumor Not the Vaccine. J. Immunol. 2004, 172 (9) 5200-5205